本月初,基于TOPAZ-1研究的结果,度伐利尤单抗联合化疗在美国被批准用于治疗患有局部晚期或转移性BTC的成人患者。欧洲、日本和其他几个国家目前也在基于TOPAZ-1研究的结果审查监管申请。 2021年10月,TOPAZ-1研究在预先设定的中期分析中达到了...
Even in immune-resistant tumors like cholangiocarcinoma, there clearly are responses to immunotherapy. Unfortunately, we don’t know who those responders are. We don’t have effective biomarkers in cholangiocarcinoma, so it makes sense to offer this to all patients. The other thing that’s worth ...
4. Zhou J,Fan J,Shi G,et al. Anti-PD1 antibody toripalimab,lenvatinib and gemox chemotherapy as first-line treatment of advanced and unresectable intrahepatic cholangiocarcinoma: A phase II clinical trial[J]. Ann Oncol,2020,31(suppl...